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Abstract
Objectives—Tamoxifen bioactivation to endoxifen is primarily mediated by CYP2D6; however, 
substantial variability remains unexplained. Our objective was to conduct a comprehensive 
assessment of the effect of genetic variation in tamoxifen-relevant enzymes and transporters on 
steady-state endoxifen concentrations.
Methods—Comprehensive genotyping of CYP enzymes and transporters was conducted using 
the iPLEX® ADME PGx Pro Panel in 302 tamoxifen treated breast cancer patients. Predicted 
activity phenotype for 19 enzymes and transporters were analyzed for univariate association with 
endoxifen concentration, and then adjusted for CYP2D6 and clinical covariates.
Results—In univariate analysis, higher activity of CYP2C8 (regression β=0.22, p=0.020) and 
CYP2C9 (β=0.20, p=0.04), lower body weight (β=−0.014, p<0.0001), and endoxifen 
measurement during winter (each β<−0.39, p=0.002), were associated with higher endoxifen 
concentration. After adjustment for CYP2D6 diplotype, weight and season, CYP2C9 remained 
significantly associated with higher concentration (p=0.02), but only increased the overall model 
R-squared by 1.3%.
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Conclusions—Our results further support a minor contribution of CYP2C9 genetic variability 
on steady state endoxifen concentration. Integration of clinician and genetic variables into 
individualized tamoxifen dosing algorithms would marginally improve their accuracy, and 
potentially enhance tamoxifen treatment outcomes.
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Introduction
Tamoxifen, a selective estrogen receptor modulator, is used to prevent the recurrence of 
estrogen receptor positive (ER+) breast cancer in the adjuvant treatment of pre- and post-
menopausal women, as well as for treatment of metastatic disease and ductal carcinoma in 
situ[1]. Tamoxifen is metabolized to several metabolites with greater anti-estrogenic potency 
including 4-hydroxy-tamoxifen and endoxifen[2]. Reaching therapeutic concentrations of 
these metabolites, particularly endoxifen, may be critical to the efficacy of tamoxifen 
treatment; patients above a therapeutic threshold have been reported to have lower 
recurrence rates than women with lower concentrations[3, 4].
The enzyme primarily responsible for metabolic conversion of tamoxifen to endoxifen is 
CYP2D6, but other enzymes and transporters are also active in this metabolic pathway[5]. 
Genetic variation in CYP2D6 has a profound effect on endoxifen serum concentrations as it 
is the main pathway for the conversion of the primary tamoxifen metabolite, N-
desmethyltamoxifen to endoxifen, and substantially contributes to the formation of 4-OH 
tamoxifen from tamoxifen[3][6]. Patients with genotypes that confer CYP2D6 poor 
metabolizer (PM) phenotype have lower endoxifen concentrations than those with 
intermediate (IM), normal (NM, formerly referred to as extensive [EM]) or ultra-rapid (UM) 
metabolizer status[7].
Aside from CYP2D6, there are several enzymes and transporters known to play a role in the 
metabolism and/or distribution of tamoxifen and endoxifen. Prior studies have reported 
associations between tamoxifen and/or its metabolites for common functionally 
consequential single nucleotide polymorphisms (SNPs) in CYP2C9[4, 5, 8]and CYP2C19[4, 
8, 9]. In addition to genetics, there are some patient specific factors such as height, weight, 
and the calendar date that may contribute to steady state endoxifen concentrations[10]. It 
may be possible to use genetic and clinical information to predict a patient’s endoxifen 
concentration prior to initiation, and use this information to guide personalized tamoxifen 
dose adjustment to achieve therapeutic endoxifen concentrations. Several groups, including 
ours, have piloted this approach by dose escalating patients with low-activity CYP2D6 
genotypes and have made progress towards normalizing endoxifen concentrations without 
increasing treatment related toxicity[2, 11–14]. In addition, one study dose escalated patients 
solely based on baseline endoxifen[15]; however, these studies have been unable to achieve 
comparable endoxifen levels in CYP2D6 PM patients suggesting other genetic data and 
clinical variables need to be incorporated into a prediction algorithm.
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Further research is needed to determine the impact of SNPs in enzymes and transporters on 
endoxifen concentrations in order to improve the accuracy of personalized tamoxifen dosing 
algorithms. Prior pharmacogenetic studies have used a candidate SNP approach with limited 
allelic coverage. Our objective was to use a comprehensive genotyping approach that 
includes the vast majority of functionally consequential SNPs in the genes relevant to 
endoxifen pharmacokinetics (CYP2C9, CYP2C19, CYP3A4, CYP3A5)[4, 5, 8, 9, 16–20] to 
discover genetic predictors of steady-state endoxifen concentration in patients receiving 
tamoxifen treatment. We also included additional enzymes and transporters that have 
insufficient available information to rule out their involvement in endoxifen concentrations, 




Patients included in this secondary analysis were originally enrolled in a prospective clinical 
study of CYP2D6 genotype-guided tamoxifen dose escalation (UNC Lineberger 
Comprehensive Cancer Center 0801)[2]. Detailed inclusion and exclusion criteria were 
previously reported, but briefly: women 18 years of age and older and taking tamoxifen 20 
mg for at least 4 months prior to study entry were eligible to enroll unless they had Eastern 
Cooperative Oncology Group (ECOG) performance status >2, impaired liver, bone marrow 
or kidney function, history of thromboembolic disease, prior liver or bone marrow 
transplant, received blood transfusions within 3 months of study entry, or were taking strong 
CYP2D6 inhibitors. Patients taking medications known to inhibit CYP2D6 including 
amiodarone, bupropion, cimetidine, haloperidol, indinavir, ritonavir, terbinafine, quinidine, 
duloxetine, paroxetine, or fluoxetine were excluded. Those taking weak inhibitors of 
CYP2D6 (venlafaxine, citalopram, sertraline, or escitalopram) were included. After an initial 
pilot study of 120 patients[2] the study was expanded to a total of 500 participants[24].
Sample and Data Collection
Patient demographic and treatment information including age, weight, menopausal status, 
self-reported race, duration of tamoxifen therapy, and concomitant medication were 
collected at study entry. Genomic DNA was isolated from the blood samples collected at 
entry into the clinical trial for germline genotyping. Baseline tamoxifen and metabolite 
concentrations were measured at baseline when all patients were taking tamoxifen 20 mg 
daily and had reached steady state. The following metabolites were measured in addition to 
tamoxifen: 4-OH-tamoxifen, N-desmethyl tamoxifen, and endoxifen. Concentrations were 
determined by liquid chromatography-mass spectrometry by collaborators at Indiana 
University using a previously described assay[2].
Genotyping and Activity Phenotype Prediction
At study enrollment, CYP2D6 status was determined for each participant using the Roche 
AmpliChip™ CYP450 Test (Indianapolis, IN). Genotype was categorized into diplotypes 
(i.e. NM/IM, NM/PM, IM/IM, IM/PM) and then phenotypes (UM, NM, IM, PM) as 
previously described[25]. Phenotypes UM and NM were combined due to small number of 
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UM phenotypes and prior work in the cohort that confirmed differences in activity are 
negligible[25]. Residual DNA samples were genotyped for 36 additional genes, primarily 
CYP450 enzymes and drug transporters, on the iPLEX® ADME PGx Pro Panel by Agena 
Bioscience (San Diego, CA) for this secondary pharmacogenetic analysis. All genetic 
information underwent appropriate quality control. SNPs with genotyping call rate <95% 
and samples with a call rate of <90% across all genotyped SNPs were excluded from 
analysis. Of the 36 genes genotyped on the panel, the following 19 genes were chosen to be 
included in the analysis based on their potential contribution to tamoxifen metabolism or 
transport: CYP2C9, CYP3A4, CYP3A5, ABCB1, SLOCO1B1, SULT1A1, SULT1A2, 
UGT2B7, UGT2B15, UGT2B17, CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C19, 
CYP2C8, CYP2E1, ABCC2 and ABCG2. Each allele was assigned a predicted activity 
determination (low, normal, high) based on published data and each patient’s activity 
diplotype was translated into predicted activity phenotypes (poor, intermediate, normal or 
ultra-rapid) for analysis, as described in Supplemental Digital Content, Tables 1 and 2.
Statistical Analysis
Patients who were successfully genotyped and had baseline endoxifen concentration data 
measured on the modified assay used for the expansion cohort were included in the analysis. 
Steady state endoxifen concentrations underwent square root transformation to improve 
distributional normality. Predicted activity for each enzyme or transporter was analyzed 
assuming an additive effect with the number of levels (2, 3 or 4) corresponding to the 
number of phenotypes described in Supplemental Digital Content, Table 2. Clinical variables 
analyzed included age and weight as continuous variables, season of sample collection 
(January–March, April–June, July–September, October–December), CYP2D6 inhibitor 
status (none or weak CYP2D6 inhibitor), menopausal status (pre- or post-menopausal), and 
self-reported ethnicity (white, African-American, or other) as categorical variables. 
Associations between predicted activity phenotype or clinical variables and baseline steady 
state concentration for tamoxifen and its metabolites were analyzed using univariate linear 
regression. Following univariate analysis, genetic associations were adjusted for clinical 
covariates that were significant in the univariate setting. Multivariable models were 
constructed with each combination of CYP2C8, CYP2C9, and CYP2C19 activity 
phenotypes to assess the independent contribution of each gene. The most parsimonious 
model was selected based on Akaike Information Criterion (AIC), and R-squared values 
were estimated from the linear regression models. As a hypothesis generating secondary 
screen, the association of each predicted activity phenotype with tamoxifen, its other 
metabolites (4-OH-tamoxifen and N-desmethyl-tamoxifen) and their metabolic ratios was 
evaluated. An uncorrected p-value threshold of p<0.05 was considered statistically 
significant for all analyses, which were conducted in SAS v9.4 statistical software (Cary, 
NC).
Results
Patient and Demographic Data
After excluding subjects that were missing endoxifen concentration or genetic data, 302 
patients were included in the final analysis (Figure 1). Patient demographic data including 
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age, weight, race, date of sample collection, CYP2D6 diplotype, and concomitant use of a 
CYP2D6 inhibitor (i.e. citalopram, escitalopram, sertraline or venlafaxine) can be found in 
Table 1. The average age in this cohort was 52.8, 85% of the patients self-reported as 
Caucasian, and 45% were pre-menopausal. The CYP2D6 phenotype distribution was similar 
to previously reported in this cohort with 37% having NM phenotype (NM/NM diplotype), 
4% having PM phenotype (PM/PM diplotype) and the remaining ~60% being IM phenotype 
that can be subdivided into several diplotypes as reported in Table 1[25].
Univariate Associations of Clinical and Genetic Data
In the univariate analysis, an increase in steady-state endoxifen concentration was detected 
for patients with increased CYP2C9 phenotype activity (Linear Regression β 
coefficient=0.20, 95% Confidence Interval: 0.01–0.39, p=0.04) and CYP2C8 phenotype 
activity (β=0.22, 95% CI: 0.03–0.40, p=0.02, Table 2, Figure 2). None of the other genes 
analyzed were associated with endoxifen concentration in the univariate analysis, though 
there was a suggestive trend for SLCO1B1 (p=0.07, Table 2) and CYP2C19 (p=0.11, Table 
2, Figure 2).
A significant association was found with higher weight associated with lower endoxifen 
concentration (β=−0.014, 95% CI: −0.020 – −0.008, p<0.0001, Figure 3). We also found 
that patients whose samples were collected in the fall (β=−0.55, 95% CI: −0.84 – −0.26, 
p=0.0002), summer (β=−0.55, 95% CI: −0.88 – −0.23, p=0.0009) or spring (β=−0.39, 95% 
CI: −0.71 – −0.07, p=0.02) had significantly lower endoxifen concentration compared with 
samples collected in the winter (Figure 3). No evidence of an association was found with 
other clinical variables: age, race, menopausal status, or concomitant administration of weak 
CYP2D6 inhibitors (Table 3).
Adjusted Associations for Genetic Variables
After adjustment for clinical variables with significant univariate associations (CYP2D6 
diplotype, weight and season) the association for CYP2C9 maintained significance (p=0.02) 
while the association for CYP2C8 was no longer significant (p=0.11). Interestingly, the 
association for CYP2C19 was nearly significant after adjustment (p=0.07) whereas the trend 
for SLCO1B1 disappeared (p=0.18, Table 2).
The trends seen with CYP2C8, CYP2C9, and CYP2C19 are likely due to known linkage 
disequilibrium between the high activity CYP2C19*17 and the wild-type CYP2C8 and 
CYP2C9 (D’>0.9)[26]. Therefore, we constructed multivariable models including different 
combinations of the three genes adjusted for CYP2D6, weight, and season (Supplemental 
Digital Content, Table 3). Comparing the goodness of fit statistics (AIC), the optimal model 
included only CYP2C9 (p=0.002, AIC 728.2378, Supplemental Digital Content, Table 3). 
CYP2C9 maintained significance when included in a model with CYP2C19 (p=0.045) and 
was borderline significant in a model with CYP2C19 and CYP2C8 (p=0.07), but neither of 
these other genes maintained significance when included in a model with CYP2C9 (all 
p>0.05), suggesting that CYP2C9 drives the identified associations for all three genes. In the 
final multivariable model, the addition of CYP2D6 diplotype explained 15.3% of the 
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variability in steady-state endoxifen concentration while CYP2C9 (1.3%), weight (5.3%), 
and season (3.8%) explained relatively little of the residual variability (Table 4).
Secondary Screen of Genetic and Clinical Predictors of Tamoxifen, Metabolites, and 
Metabolite Ratios
Screening of other metabolites and metabolite ratios for hypothesis generation led to 
identification of associations with weight and season and two nominal associations with 
genetic factors. Similar to the association seen with endoxifen, greater weight was associated 
with lower concentrations of OH-tamoxifen (β=−0.0038, 95% CI: −0.0062 – −0.0015, 
p=0.0021, Supplemental Digital Content, Table 4) and N-desmethyltamoxifen (β=−0.025, 
95% CI: −0.044 – −0.0048, p=0.017). In addition, OH-tamoxifen concentrations were lower 
in the fall (β=−0.21, 95% CI: −0.32 – −0.96, p=0.0004, Supplemental Digital Content, Table 
4), and summer (β=−0.13, 95% CI: −0.26 – −0.0038, p=0.049) and N-desmethyltamoxifen 
concentrations were lower in the fall (β=−1.053, 95% CI: −1.99 – −0.12, p=0.031,) as 
compared to winter, similar to the associations detected for endoxifen. Screening predicted 
activity phenotype, higher SULT1A1 activity was nominally associated with greater 
endoxifen/4-OH-tamoxifen ratio (β =0.54, 95% CI: 0.04–1.04, p=0.03) and increased 
CYP2C8 activity was associated with a higher ratio of endoxifen to N-desmethyltamoxifen 
(β=0.01, 95% CI: 0.00, 0.02, p=0.04, Supplemental Digital Content, Table 5).
Discussion
The effect of genetic variability in CYPs and transporters, aside from CYP2D6, and clinical 
variables on steady-state endoxifen concentrations has not been thoroughly explored. 
CYP2D6 is thought to account for around 50% of the metabolism of tamoxifen to 
endoxifen[7], leaving a large portion of the metabolism unexplained. In this study, dozens of 
functionally relevant SNPs were genotyped to predict patient’s phenotypic activity of 
nineteen CYPs and transporters, in order to determine whether this activity was associated 
with variability in endoxifen concentrations. Our findings further support previous analyses 
suggesting that genetic variation in CYP2C9, weight, and the season of sample collection 
contribute to this residual variability. Although there were intriguing trends for CYP2C8 and 
CYP2C19, multivariable models suggest these may be spurious associations caused by 
linkage disequilibrium with CYP2C9.
Our findings support previous work indicating a contribution of CYP2C9 to endoxifen 
production. Human liver microsomes homozygous for low-activity CYP2C9 genotypes have 
lower rates of 4-OH-tamoxifen formation than wild-type microsomes[18]. This in vitro 
finding has been confirmed in clinical cohorts of tamoxifen treated patients. Lower steady-
state endoxifen[5] or 4-OH-tamoxifen[4] concentrations have been detected in patients 
carrying common, low-activity CYP2C9 polymorphisms (CYP2C9*2 and *3). Recently, 
Powers et al. utilized a more comprehensive CYP2C9 activity phenotyping approach by 
integrating uncommon low-activity variants (i.e. *4 and *11) and concomitant inhibitor 
treatment (i.e. fluoxetine and omeprazole), confirming that patients with diminished 
CYP2C9 activity have lower endoxifen concentrations[17]. Our results are in line with these 
previous findings, though we did not have information on CYP2C9 inhibitor co-
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administration. Other studies that did not detect associations between CYP2C9 phenotype 
and concentrations of endoxifen or upstream metabolites were likely underpowered due to 
the rarity of low-activity CYP2C9 variants in patients of Asian descent[7, 8]. Other clinical 
analyses have reported associations between common functionally consequential 
polymorphisms in CYP2C19 (i.e. low-activity *2 and *3 and high-activity *17) and 
concentrations of tamoxifen and its metabolites[8, 9]. Our multivariable model suggests that 
CYP2C19 itself has a negligible, if any, contribution to endoxifen concentration and these 
associations can likely be attributable to linkage disequilibrium between the high activity 
CYP2C19*17 and the wild-type CYP2C8 and CYP2C9[26].
This study, similar to other reports examining BMI, found that higher body weight was 
associated with lower endoxifen[3, 4]. Body weight was utilized instead of body mass index 
because height information was unavailable. We also detected a significant association with 
season of sample collection, in which samples collected during the winter had higher 
concentrations of endoxifen than those collected in other seasons. Slightly higher 
concentrations of tamoxifen metabolites, but not tamoxifen itself, were also identified in the 
winter, suggesting this may be a metabolic phenomenon. Previously, two groups have 
reported the opposite effect, with samples collected in the spring and summer having greater 
endoxifen concentration than those collected in the winter[10, 27]. The mechanism for this 
seasonal effect is unclear as the original hypothesis, that seasonal sun-associated vitamin D 
induced CYP3A4 activity, was not confirmed by analyses of vitamin D and CYP3A activity 
in these publications[27]. The reason for the discrepancy in the direction of effect between 
our study and these prior publications is also not clear, but may have to do with geographical 
differences in sun exposure, as our study was conducted in North Carolina, USA. Also 
differences in the prevalence of vitamin D supplementation between cohorts could 
contribute, however we did not collect this information. One final possible explanation is 
increased tamoxifen adherence during winter months due to increased tolerability of hot 
flashes. Contrary to that hypothesis, tamoxifen concentrations were not different between 
the seasons. Lastly, we did not detect an association with CYP2D6 inhibitor co-
administration, which is known to be a major determinant of endoxifen concentration[10, 
28]. This is unsurprising, as patients taking strong or moderate CYP2D6 inhibitors were 
excluded from this study and relatively few patients (n=23) were taking weak inhibitors, 
which likely have a marginal effect on enzyme activity.
Several limitations of this analysis should be considered. The primary limitation is the lack 
of confirmation from prospective clinical trials that endoxifen serum concentration is 
associated with tamoxifen treatment efficacy, or perhaps toxicity, in breast cancer 
patients[29, 30]. Additionally, despite our attempt to perform a comprehensive assessment of 
the known, functionally consequential polymorphisms within genes putatively related to 
endoxifen concentration, it is likely that our panel did not include some relevant genes and 
some variants within the genes analyzed, particularly less common variants that have not yet 
been discovered. The panel utilized was as comprehensive as possible considering current 
knowledge in the field. The predicted functionality for polymorphisms was extrapolated 
from known data, but could have been incorrectly categorized. Further research efforts are 
needed, likely in well-controlled in vitro experiments, to estimate metabolic activity of 
individual alleles, perhaps accounting for substrate-dependent effects.
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Our analysis explained approximately a quarter of the variability in endoxifen concentration, 
which is lower than previously reported for CYP2D6 genotype[7]. One possible explanation 
is that our samples were collected irrespective of the timing of the last dose. Additionally, 
endoxifen concentration was measured at baseline, assuming patients were adherent to 
tamoxifen treatment, as self-reported. Tamoxifen adherence is highest within the first year of 
therapy, around 77–88%, and decreases over time[31]; our patient cohort was taking 
tamoxifen on average 0.8 years prior to study entry, suggesting adherence was relatively 
high. Lastly, we did not perform multiple comparisons correction, increasing the possibility 
of false positive findings; however, the agreement of our findings with prior literature 
somewhat alleviates this concern.
Conclusion
In this retrospective secondary analysis of data collected from a prospectively enrolled 
cohort, genetic variation that confers diminished CYP2C9 activity was associated with 
decreased steady-state endoxifen concentrations. In adjusted analyses, CYP2C9 activity 
seemed to be independently contributory while CYP2C8 and CYP2C19 were not associated 
with endoxifen concentration, likely due to known linkage disequilibrium. These results 
suggest that individualized treatment approaches should consider several genetic and clinical 
factors in addition to CYP2D6 status to improve treatment efficacy. Further research is 
needed to integrate these genetic variables into an endoxifen prediction algorithm to guide 
personalized tamoxifen dosing. A combined analysis of existing datasets could be conducted 
to develop a more comprehensive and accurate algorithm. However, for these algorithms to 
be clinically useful endoxifen concentration needs to be definitively associated with 
tamoxifen treatment outcomes, ideally therapeutic efficacy.
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Figure 1. CONSORT Diagram of Patient Matriculation from Clinical Trial to this 
Pharmacogenetic Analysis
Of the 500 patients enrolled in the original clinical trial, 361 had evaluable endoxifen data, 
355 had usable CYP2D6 genetic information, and 302 were successfully genotyped on the 
ADME PGx Pro Panel and were included in this analysis.
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Figure 2. Endoxifen Concentration by CYP2C8, CYP2C9, and CYP2C19 Activity
Box and whisker plot (circles represent outliers) of steady-state endoxifen concentration 
stratified by predicted activity phenotype for CYP2C8 (left), CYP2C9 (middle), and 
CYP2C19 (right). Endoxifen concentration increased as predicted phenotypic activity 
increased for each gene (p=0.02, p=0.04, p=0.11, respectively).
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Figure 3. Association of Endoxifen Concentration with Clinical Variables
Steady-state endoxifen concentration was associated with body weight and the season of 
sample collection. Figure 3 (left): Increased patient body weight (kg) was associated with 
lower endoxifen concentrations (β=−0.014, p<0.0001). Figure 3 (right): Endoxifen 
concentrations were lower in samples collected during fall (β=−0.55, p=0.0002) summer (β=
−0.55, p=0.0009) and spring (β=−0.39, p=0.02) compared with those collected during 
winter.
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Table 1
Patient Demographics
Clinical Variable Level Median (range) or n (%)
Age Years 52.8 (24.8–95.1)
Weight Kg 70.8 (32.1–149.1)
Self-Reported Race
Caucasian 253 (84.6%)
African American 38 (12.7%)
Other/Unknown 8 (2.7%)
Season of Baseline Sample Collection for Endoxifen Measurement
Winter (Jan–Mar) 58 (19.4%)
Spring (April–June) 67 (22.3%)
Summer (July–Sept) 61 (20.3%)
Fall (Oct–Dec) 114 (38.0%)













Time on Tamoxifen Prior to Enrollment Years 0.8 (0.3–9.7)
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Table 3
Univariate Association of Clinical Variables with Endoxifen Concentration
Clinical Variable B Coefficient (95% Confidence Interval) P-value
Weight (kg) −0.014 (−0.020, −0.008) < 0.0001
Age (10 years) 0.05 (−0.05,0.14) 0.31
Self-reported Race (vs. white)
African American −0.13 (−0.45,0.18) 0.41
Other 0.15 (−0.50,0.81) 0.65
Season of Sample Collection (vs. winter)
Fall −0.55 (−0.84, −0.26) 0.0002
Summer −0.55 (−0.88, −0.23) 0.0009
Spring −0.39 (−0.71, −0.07) 0.02
Post-Menopausal (vs. pre) 0.14 (−0.08,0.35) 0.21
Concomitant CYP2D6 Weak Inhibitor Use 0.33 (−0.07,0.73) 0.11
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Table 4
Final multivariable model of genetic and clinical variables associated with steady-state endoxifen 
concentration.
Clinical Variable
B Coefficient (95% 
Confidence Interval) P-value
r2 Contribution to 
Final Model
CYP2C9 Activity Phenotype .20 (0.03, 0.37) .025 1.3
Weight (kg) −.013 (−.02, −.01) <0.0001 5.3
Season of Sample Collection (vs. winter)
Fall −.48 (−.74, −.22) 0.0004
3.8Summer −.49 (−.79, −.19) 0.0017
Spring −.41 (−.7, −.19) 0.0064
CYP2D6 Diplotype as defined in [25] (vs. NM/NM, UM 
Alleles Considered NM alleles)
NM/IM −.35 (−.61, −.08) .0155
15.3
NM/PM −.49 (−.73, −.26) <0.0001
IM/IM −.87 (−1.4, −.34) 0.0015
IM/PM −.96 (−1.3, −.61) <0.0001
PM/PM −1.32 (−1.79, −.85) <0.0001
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